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CLEARING THE FINAL HURDLES TO MITOCHONDRIAL APOPTOSIS: 
REGULATION POST CYTOCHROME C RELEASE
P. Monian, X. Jiang*
Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
In mammalian cells, the mitochondrial pathway of apoptosis plays a key role in various biological processes and has been exten-
sively studied. One of the signature features of this pathway is permeabilization of the outer mitochondrial membrane (MOMP) 
and thus release of cytochrome c into the cytoplasm to trigger subsequent activation of executioner caspases. Because MOMP 
is associated with loss of mitochondrial function, it has long been believed to represent an irreversible commitment to cell death. 
However, emerging data over the last decade has indicated that induction of MOMP alone is not always sufficient to fully commit 
cells to death. As such, it becomes important to understand how apoptosis is regulated post-MOMP. Here we recount evidence 
investigating if and how cells can survive MOMP, and why this might have important physiological consequences. Furthermore, 
we review recent progress made in understanding how the pathway is regulated beyond MOMP and cytochrome c release. This 
article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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Apoptosis is one of the most fundamental pro-
cesses to life. Essential to several processes rang-
ing from normal development to regulation of the 
immune system and tissue homeostasis, apoptosis 
is conserved across all metazoans [1–3]. Deregulated 
apoptosis has been implicated in a variety of patho-
logical conditions including cancer, neurodegenerative 
disorders and autoimmune diseases [4]. In mammalian 
cells, there are two major apoptotic pathways. The cell 
intrinsic pathway is characterized by mitochondrial 
outer membrane permeabilization (MOMP), a process 
regulated by the Bcl-2 family of proteins [5]. Follow-
ing MOMP, several proteins in the intermitochondrial 
membrane space diffuse out into the cytosol. One such 
crucial factor, cytochrome c, binds to the cytosolic 
protein Apaf-1, triggering the formation of a hepta-
meric caspase-9 activation complex, the apopto-
some. Active caspase-9 then directly cleaves and 
activates the executioner caspases-3 and -7, leading 
to a series of morphological changes and ultimate 
apoptotic cell death [6, 7]. In the cell extrinsic pathway, 
binding of so-called “death-ligands” to their cognate 
receptors, triggers the recruitment of specific adap-
tor molecules such as FADD or TRADD which in turn 
induce dimerization of initiator caspases-8/10 [8]. 
The induced proximity activates caspase-8, which 
directly cleaves and activates downstream executioner 
caspases-3/7. Importantly, caspase-8 is also capable 
of activating the mitochondrial pathway of apoptosis 
by directly cleaving the BH3-only protein Bid. Trun-
cated Bid localizes to the mitochondrial membrane 
and activates Bax, ultimately leading to MOMP [9–11]. 
Intriguingly, there exists a unique dichotomy relating 
to the functional significance of the crosstalk between 
the two pathways. In type I cells, direct processing 
of executioner caspases by caspase-8 is sufficient 
for robust death-receptor induced apoptosis. In type 
II cells however, amplification of the apoptotic pathway 
by caspase-8 mediated activation of Bid, and subse-
quent MOMP is essential for apoptosis. 
IS MOMP TRULY THE “POINT 
OF NO-RETURN” FOR CELL DEATH?
It has long been held that MOMP is a “point of no-
return” for cell death, i.e., cells die following MOMP, 
irrespective of caspase activation [12–14]. However, 
given our ever-expanding understanding of the mi-
tochondrial apoptotic pathway, this prevailing school 
of thought has increasingly been called into question. 
For instance, a deficiency in integral components 
of the pathway, like Apaf-1 or caspase-9, does not 
just delay, but completely inhibits developmental 
cell death in several cases [15–19]. In fact, deletion 
of Apaf-1 or caspase-9 can substitute for inactivation 
of p53 in myc-driven transformation of cells [20]. These 
observations strongly suggest that loss of mitochondrial 
membrane integrity without downstream caspase acti-
vation might not be sufficient to commit cells to death. 
Furthermore, it is now known that cytochrome c release 
is accompanied by release of additional factors like 
Smac/Diablo and Omi/HtrA2 which relieve caspase inhi-
bition by members of the IAP family of proteins [21–24]. 
If MOMP were indeed the universal “point of no-return” 
for cell death, it would imply that such regulation 
of caspase activity beyond MOMP is unessential for 
cell death. However, differences in levels of the en-
dogenous caspase-3 inhibitor XIAP not only modulate 
the cell intrinsic pathway, but can also have a profound 
effect on apoptosis induced by death ligands, i.e., the 
type I versus type II cells phenotype. Specifically, owing 
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to enhanced expression of XIAP in type II cells, MOMP-
accompanied release of XIAP inhibitors Smac and Omi 
is essential for apoptosis induced by death ligands 
[25]. Thus, the regulation of proteins beyond MOMP 
has a significant effect on the cell extrinsic pathway 
of apoptosis as well. In this regard, it is worth noting 
that small molecules targeting anti-apoptotic Bcl-2 fam-
ily proteins as well as IAPs are emerging as attractive 
agents for cancer therapy (see reviews by Almagro & 
Vucic [26], and Weyhenmeyer et al. [27] in this issue). 
Coupling such agents to traditional genotoxic regiments 
that induce caspase activation will likely maximize their 
therapeutic potential.
How might cells survive an insult to the mitochon-
drial membrane? It has been suggested that enhanced 
expression of GAPDH could mediate clonogenic sur-
vival following MOMP, provided caspase activation 
was inhibited [28]. Although the mechanism for this 
remains unclear, the data suggest GAPDH could medi-
ate its effects by enhancing glycolysis and autophagy. 
Additionally, recent work has shown that such a cellular 
recovery following MOMP is dependent on the ability 
of the cell to repopulate its mitochondrial network 
through division of the few intact mitochondria that 
are able to maintain membrane integrity [29]. What 
intrinsic properties of individual mitochondria within 
the same cell cause them to be differentially affected 
by the same apoptotic stimulus remains an unan-
swered question. It is tempting to speculate that con-
ditions such as individual mitochondrial localization 
relative to other cellular organelles, expression of anti-
apoptotic Bcl-2 family members, and lipid composition 
of the membrane could be responsible for this effect. 
WHY IS POST-MOMP REGULATION 
OF APOPTOSIS IMPORTANT?
Upon first glance, it seems counter-intuitive that 
a cell would commit precious resources to regulating 
apoptosis after the integrity of the mitochondrial mem-
brane has been compromised. However, the additional 
nodes of regulation indeed have important physio-
logical consequences. One obvious benefit to having 
additional regulation of apoptosis beyond MOMP 
is to ensure that a certain threshold of cytochrome 
c-mediated caspase activation needs to be achieved 
prior to a complete commitment to cell death. Such 
a safeguard against “accidental MOMP” is particularly 
relevant in the instance of post-mitotic cells, especially 
ones with poor regenerative potential. Indeed, long-
lived cells such as cardiomyocytes and sympathetic 
neurons are particularly resistant to apoptosis induced 
by cytochrome c microinjection, likely due to markedly 
low Apaf-1 levels [30–32]. In both cell types, XIAP 
plays an important role in maintaining a high threshold 
of cytochrome c release needed to activate apopto-
sis. Such an intricate regulation of apoptosis beyond 
MOMP protects the longevity of these cells. 
Caspases have been reported to have non-apop-
totic functions as well. For instance, caspase-3 plays 
an essential role in the terminal differentiation of vari-
ous cell types including myoblasts, lens cells, epider-
mal keratinocytes, and neural stem cells [33–37]. Cy-
tochrome c-mediated caspase-3 activation also plays 
a significant role in long-term depression (LTD) in hip-
pocampal neurons, a process essential for normal 
brain development and function [38]. Consequently, 
this process can be blocked by over-expression 
of Bcl-xL or XIAP, and caspase-3 knockout mice are 
deficient in their ability to undergo receptor-dependent 
LTD. Interestingly, both lens cell development and 
NMDA receptor-stimulated LTD are accompanied 
by detectable levels of cytochrome c release and 
caspase-3 activity which is significantly lower than that 
associated with apoptosis [39]. Rather than inducing 
cell death, the primary function of the mitochondrial 
pathway in these scenarios is to mediate such essential 
processes, through caspase-3 dependent cleavage 
of specific substrates. It is likely that concomitant regu-
lation of caspase activity by pro-survival molecules 
like IAPs, survivin, Bcl-2, etc is required for these and 
other non-apoptotic functions of caspase-3 including 
regulation of B cell proliferation, dendritic cell matu-
ration, forebrain development, etc. [40–42]. Thus, 
the ability to survive MOMP has functional relevance 
in proliferating cells as well. 
Finally, post-MOMP regulation of apoptosis may 
have important implications in oncogenesis. Presum-
ably, inhibiting caspase activity downstream of MOMP 
would confer upon cells the ability to survive apoptosis 
induced by various forms of chemotherapy, and thus 
impart significant oncogenic potential. Indeed, tumors 
often evolve mechanisms to inhibit caspase activity, 
most notably through upregulation of XIAP and sur-
vivin, or repression of Apaf-1 [43–45]. It is likely that 
many of the other proteins involved in post-MOMP 
regulation of apoptosis could also impact tumorigen-
esis in a similar manner. Thus, understanding how 
apoptosis is regulated beyond MOMP is important and 
will be discussed here.
REGULATION OF APOPTOSOME 
FORMATION
Under normal conditions, Apaf-1 is present in the 
cytosol in a monomeric, auto-inhibitory state. Bind-
ing of cytochrome c to Apaf-1 is the first step towards 
relieving this repression and triggering the formation 
of the apoptosome [46, 47]. Transfer RNA (tRNA) 
and intracellular K+ are thought to inhibit this interac-
tion by directly binding cytochrome c at physiological 
concentrations [48–50]. Additionally, independent 
studies have identified several proteins that regulate 
apoptosome formation through diverse mechanisms. 
For instance, Aven directly binds Apaf-1 and inhibits 
its oligomerization [51]. APIP (Apaf-1 interacting 
protein) competes with caspase-9 for Apaf-1 binding 
[52]. Although the exact mechanism remains unclear, 
the oncoprotein prothymosin alpha (ProT) potently 
inhibits Apaf-1 oligomerization [53]. The redox state 
of cytochrome c also influences caspase activation 
in vitro; oxidized cytochrome c stimulates, while re-
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duced cytochrome c inhibits caspase activation [54, 
55]. However, the exact mechanism underlying the 
modulation of the pro-apoptotic potential of cyto-
chrome c in this manner remains unclear, and it should 
be noted that independent experiments have found 
reduced cytochrome c to be proficient at caspase 
activation as well [56].
Following cytochrome c binding, Apaf-1 undergoes 
a conformational change accompanied by nucleotide 
exchange, driving formation of the apoptosome [57]. 
Although Apaf-1 contains a bound nucleotide in its 
monomeric state, following cytochrome c binding, 
exchange of the bound nucleotide is a required step 
in the path to apoptosome formation. Based on in vitro 
studies, the absence of nucleotide exchange results 
in the formation of irreversible Apaf-1 aggregates, 
thus blocking downstream caspase activation [58]. 
This process of nucleotide exchange can be en-
hanced by a combination of three proteins: putative 
HLADR-associated protein 1 (PHAP1), Hsp70 and 
the cellular apoptosis susceptibility protein (CAS/
CSE1L), thus driving apoptosome formation and 
subsequent cell death [59]. Consistently, PHAP1 has 
previously been characterized as a tumor suppressor 
in several different tumorigenesis models [60–63]. 
Furthermore, mutational analysis has demonstrated 
that the apoptotic activity of PHAP1 is required for its 
tumor-suppressive function [64]. Similarly, knockdown 
of CAS has been shown to inhibit cell death induced 
by a variety of apoptotic stimuli [59, 65–68]. Intrigu-
ingly, CAS has also been reported to have an essential 
function in mitosis and deletion of CAS in mice leads 
to embryonic lethality [69, 70]. Consistently, CAS 
expression is upregulated in highly proliferating tis-
sue as well as several cancer cell lines. Furthermore, 
amplification and/or overexpression of CAS have 
been observed in several human tumors including 
melanoma, glioblastoma, ovarian, endometrial, liver, 
breast, prostate, and colon cancers among others 
[71–77]. These observations imply both putative 
tumor-suppressive and oncogenic roles for CAS, 
suggesting that perhaps CAS could have a janus-like 
function: playing an essential role in cell proliferation 
on one hand, and promoting apoptosis on the other.
Counteracting the effect of PHAP1, Hsp70 and 
CAS, intracellular levels of calcium inhibit apopto-
some formation by binding and locking Apaf-1 in a 
“closed” conformation that is resistant to nucleotide 
exchange [78]. Nitric oxide is also thought to hinder 
Apaf-1 oligomerization, although the exact mechanism 
of inhibition remains unclear [79]. 
REGULATION OF CASPASE-9 ACTIVATION
Following nucleotide exchange and the accom-
panying conformational changes, the N-terminal 
caspase recruitment domain (CARD) on Apaf-1 is ex-
posed allowing for a homotypic interaction with pro-
caspase-9, which also contains a CARD domain. 
This induced proximity triggers dimerization and 
subsequent activation of caspase-9, which then 
directly activates caspase-3 [80–82]. Interestingly, 
apoptosome mediated activation of caspase-9 leads 
to robust auto-processing, which serves to decrease 
caspase-9 affinity for the apoptosome as well as its 
catalytic activity [83]. It can be argued that this “mo-
lecular timer” model of caspase-9 activation serves 
as another node of apoptotoic regulation following 
MOMP: intracellular concentrations of caspase-9, rate 
of procaspase-9 auto-processing, and rate of cleaved 
caspase-9 dissociation from the apoptosome to-
gether help set the pace of caspase-3 activation, 
and subsequent cell death. Genome-wide analysis 
in D. melanogaster revealed that procaspase 9 levels 
are subject to regulation by Tango 7 (human ortho-
logue PCID1). Consistently, knockdown of PCID1 leads 
to decreased expression of procaspase-9, and is suf-
ficient to inhibit cell death [84]. It is also worth noting 
that PCID1 is commonly repressed in pancreatic can-
cer [85]. Several CARD domain-containing proteins 
also impact the apoptosome-caspase 9: TUNCAN 
binds caspase-9 and inhibits its recruitment to apop-
tosome, while HCA66 and NAC/DEFCAP counteract 
this effect by binding Apaf-1 and enhance the amount 
of caspase-9 recruited or retained in the apoptosome 
[86–89]. It is likely that the cumulative effects of such 
protein-protein interactions determine the potency 
of caspase-9 activation.
The master suppressor of apoptosis, X-linked 
inhibitor of apoptosis (XIAP) also potently regulates 
caspase-9 activation. Following recruitment to the 
apoptosome and auto-processing, a N-terminal four 
amino acid neo-epitope becomes exposed on the 
small subunit of caspase-9. Structural and biochemi-
cal analysis have revealed that the baculovirus IAP 
repeat 3 (BIR3) domain of XIAP binds to this tetra-
peptide sequence and prevents caspase-9 dime-
rization [90, 91]. Thus, XIAP sequesters processed 
caspase-9 in an inactive monomeric state, putting 
the breaks on cell death. Following apoptotic insult, 
the mitochondrial protein Smac is released into the 
cytosol where it relieves this impediment by competing 
for binding the BIR3 domain of XIAP, thus permitting 
caspase-9 dimerization [90, 92]. Omi/HtrA2 is another 
protein released from the mitochondria of apoptotic 
cells and following processing, binds and inhibits the 
XIAP-caspase interaction through a similar mechanism 
[23, 24, 93–95]. It should be noted that Omi addition-
ally possesses a serine-protease activity that also 
contributes to its pro-apoptotic function.
Finally, caspase-9 activation is subject to regula-
tion by multitude of protein kinases. Phosphoryla-
tion at Thr125 by Akt, CDK1-cyclin B1, ERK1/2, and 
DYRK1A inhibits the cleavage, and subsequent acti-
vation of procaspase 9 [96–100]. Although the exact 
mechanism underlying this inhibitory phosphorylation 
remains unresolved, it is clear that it has important 
physiological implications. For instance, mitotic arrest 
caused by chemotherapeutic agents like taxol, induces 
apoptosis in a caspase-9 dependent manner, which 
can be accelerated by a phospho-deficient mutation 
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at Thr125 [97]. Phosphorylation at the same residue 
by DYRK1A has been shown to play an important role 
in development of retinal cells in mice [101]. Given 
the importance of these kinases in other signaling 
pathways such as response to growth factors, cellular 
stresses, development, and cell cycle progression, 
such a node of regulation serves to intimately couple 
apoptosis to these diverse cellular processes. Other 
documented inhibitory kinases for caspase 9 include 
PKCz (Ser144), PKA (Ser99, Ser183, and Ser195) 
and CK2 (Ser348) [102–104]. Although some of these 
phosphorylation sites are dispensable, it is likely that 
they play significant regulatory roles in response 
to specific apoptotic stimuli. Caspase-9 process-
ing can also be stimulated by phoshphorylation 
at Tyr153 by c-Abl, especially in response to genotoxic 
stress [105].
REGULATION OF CASPASE-3/7 ACTIVITY
The final cog in the wheel of mitochondria-
mediated apoptosis is activation of the executioner 
caspase-3/7. In contrast to apical caspases, execu-
tioner caspases are present as inactive dimers under 
basal conditions, and require cleavage of the catalytic 
domain for activation [106, 107]. In the case of the 
intrinsic pathway, this need for cleavage is satisfied 
by activated caspase-9.
XIAP exerts its anti-apoptotic effect on executioner 
caspases as well, albeit through mechanisms diffe rent 
from its inhibition of caspase-9. Crystal structures 
have revealed that a “linker” region immediately N-
terminal to the BIR2 domain of XIAP interacts with the 
substrate-binding grove of caspase-3/7, occluding 
binding of substrates [108–111]. The BIR2 domain 
itself is thought to play an auxiliary role in caspase 
inhibition, through contact with the small subunit 
of the activated caspase, which stabilizes interaction 
of the “linker” region with the catalytic site [111, 112]. 
As with caspase-9, Smac can relieve XIAP-inhibition 
of caspase-3, but through a different mechanism. 
While Smac competes with caspase-9 for the same 
binding site on XIAP, i.e. the BIR3 domain, the Smac-
BIR3 interaction alone is insufficient to relieve inhibition 
of caspase-3 by XIAP. Rather, one of the N-termini 
of Smac protein (which is a homodimer) first binds 
to the BIR3 domain of XIAP (sufficient to relief inhi-
bition of caspase-9); this interaction then anchors 
a subsequent interaction of the second N-terminus 
of Smac with the BIR2 domain of XIAP. This latter 
interaction is responsible for disrupting inhibition 
of caspase-3 by the “linker” region of XIAP [113]. XIAP 
also possess a RING finger domain though which it can 
ubiquitinate and target caspase-3/7 for proteasomal 
degradation [114]. However, the contribution of this 
E3 ligase activity of XIAP to its pro-apoptotic function 
remains unclear. Another member of the IAP family, 
neuronal apoptosis inhibitory protein (NAIP) plays 
an important regulatory role in neuronal apoptosis 
by directly inhibiting caspase-3/7 activation through 
its BIR2 and BIR3 domains [115–117].
CONCLUDING REMARKS
The long held view that MOMP is the final barrier 
to cell death has evolved quickly over the last decade. 
While, MOMP is still likely to be the point of no-return 
in the majority of scenarios, it is important to realize 
that this is not universally true and the exceptional 
cases have significant physiological consequences. 
We have discussed known details of how the mito-
chondrial pathway of apoptosis is regulated beyond 
cytochrome c release (summarized in the Figure), 
and despite the vast increase in our knowledge on this 
subject, several unanswered questions remain. For 
instance, experiments suggest that different nodes 
of regulation are largely cell-type and stimuli specific. 
How does the nature of the apoptotic insult determine 
which nodes of regulation play critical roles in deter-
mining cell fate? Furthermore, how do factors like 
GAPDH and possibly others stimulate recovery of mi-
tochondrial integrity following MOMP and inhibition 
of caspase activation? Can the ability to survive MOMP 
be sufficient to impart oncogenic potential to a single 
cell? Answering these questions and others will help 
further our understanding of this critical pathway. 
Furthermore, this knowledge will serve to improve 
the design of small-molecule compounds that inhibit 
and/or accelerate apoptosis, and such drugs could 
ultimately have broad impacts across the treatment 
of various pathological conditions including cancer, 
infectious diseases, and autoimmune disorders.
Figure. Post-MOMP regulation of apoptosis. Following release 
from the mitochondria, cytochrome c binds Apaf-1 and triggers 
the formation of a heptameric wheel-like complex, the apopto-
some, which recruits and activates caspase-9. Proteins like Aven, 
physiological levels of nucleotides like tRNA and ATP, as well 
as intracellular K+ can all inhibit this process by directly inhibiting 
the interaction between Apaf-1 and cytochrome c. Formation 
of the apoptosome also requires nucleotide exchange on Apaf-1, 
a process stimulated by a combination of three proteins: PHAP1, 
Hsp70, and CAS, and inhibited by intracellular Ca2+. Recruitment 
of procaspase-9 to the apoptosome is antagonized by APIP and 
TUNCAN, and stimulated by HCA66 and NAC/DEFCAP. Further-
more, downregulation of PCID1 causes concomitant decrease 
in procaspase-9 levels. Direct phosphorylation at Thr125 by Akt, 
CDK-cyclin B1, ERK1/2, and DYRK1A inhibits caspase-9 acti-
vity through unclear mechanisms. Conversely, phosphoryla-
tion at Tyr153 stimulates activiation. XIAP mediated inhibition 
of caspase-9 and caspase-3 activity occurs through distinct 
mechanisms, and in both cases, this repression is relieved 
by SMAC/DIABLO and Omi/HtrA2, which are also released from 
the mitochondria following MOMP. See text for more details
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